(281) 713-2962
800 Rockmead Drive, Suite 155
Kingwood, TX 77339
[email protected]
Registry of the Natural History of Recurrent Pericarditis in Pediatric and Adult Patients
Status: Recruiting
Location: Alaska Heart & Vascular Institute, Allegheny General Hospital, Barnes-Jewish Hospital/Washington University, Cincinnati Children's Hospital Medical Center, Houston Methodist Hospital, Johns Hopkins University, Legacy Hospital and Health Center DBA Legacy Research Institute, Midwest Cardiovascular Research Foundation, NYU Langone Health, Northwell Health - Lenox Hill Hospital, Pima Heart and Vascular, Scripps Health, Seattle Children's Hospital, TKL Research Inc., University of California San Diego, University of Nebraska Medical Center, University of Vermont Medical Center, Virginia Commonwealth University
Conditions: Alaska Heart & Vascular Institute, Allegheny General Hospital, Barnes-Jewish Hospital/Washington University, Cincinnati Children's Hospital Medical Center, Houston Methodist Hospital, Johns Hopkins University, Legacy Hospital and Health Center DBA Legacy Research Institute, Midwest Cardiovascular Research Foundation, NYU Langone Health, Northwell Health - Lenox Hill Hospital, Pima Heart and Vascular, Scripps Health, Seattle Children's Hospital, TKL Research Inc., University of California San Diego, University of Nebraska Medical Center, University of Vermont Medical Center, Virginia Commonwealth University
City/State:
Anchorage, Alaska
Tucson, Arizona
La Jolla, California
San Diego, California
Davenport, Iowa
Baltimore, Maryland
Boston, Massachusetts
Minneapolis, Minnesota
Rochester, Minnesota
Saint Louis, Missouri
Omaha, Nebraska
Fair Lawn, New Jersey
New York, New York
New York, New York
Cincinnati, Ohio
Cleveland, Ohio
Portland, Oregon
Pittsburgh, Pennsylvania
Houston, Texas
Burlington, Vermont
Richmond, Virginia
Seattle, Washington
Contact Information:
Amanda Chriswell 907-550-2247 [email protected]
Aleksander Herber 520-576-4133 [email protected]
Study Coordinator 858-246-2413
Chelsea Butler 858-824-5241 [email protected]
Lori Christensen 563-324-2828 [email protected]
Kondal Reddy 410-502-2945 [email protected]
Wesley Xiong 617-732-4719 [email protected]
Stephanie Ebnet 612-863-3833
Halley Davidson 507-422-6246 [email protected]
Karen Bult 314-286-1767 [email protected]
Nathan Muhn 402-836-9364 [email protected]
Uzoma Okamgba-Nwoke 201-587-0500 ext 2548 [email protected]
Alexander Auchus 212-263-0855 [email protected]
212-434-4174 [email protected]
Mary Banks 513-636-2147 [email protected]
216-445-9007 [email protected]
503-413-1612 [email protected]
Geetha Rayarao 412-359-4076
Eilidh Cowan 346-238-4552 [email protected]
Alexandria Loutrel 802-847-8913 [email protected]
Emily Federmann 804-828-2775 [email protected]
Nair Deepthi 206-987-1014 [email protected]
The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population.
Read moreImpact of CardiolRx on Recurrent Pericarditis
Status: Not yet recruiting
Location:
Conditions:
City/State:
Rochester, Minnesota
Cleveland, Ohio
Contact Information:
S. A. Luis, MD [email protected]
Sonya Mihalus, BSN [email protected]
Patients with recurrent pericarditis who are refractory or intolerant to current therapeutic management options or who require long-term administration of corticosteroids to control their disease are particularly challenging to manage. The pathogenesis of pericarditis involves the activation of the inflammasome. CardiolRxTM (a pure cannabidiol [CBD] solution) is known to have anti-inflammatory properties, including modulation of inflammasome signaling. This pilot study is to assess the tolerance and safety of CardiolRxTM during the resolution of pericarditis symptoms, assess improvement in objective measures of disease, and during the extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids while taking CardiolRxTM.
Read moreEffcacy and Safety of RPH-104 Treatment in Patients with Recurrent Pericarditis
Status: Not yet recruiting
Location: Virginia Commonwealth University
Conditions: Virginia Commonwealth University
City/State:
Richmond, Virginia
Contact Information:
Antonio Abbate, MD 804-828-0513 [email protected]
“The primary purpose of this study is the evaluation of the efficacy and safety of RPH-104 treatment in patients with recurrent pericarditis.
Pharmacokinetic and pharmacodynamic parameters of RPH-104 multiple doses in this patient population will be assessed as well.”